Aflibercept acts as a soluble receptor that binds to VEGF-A, PlGF, and VEGF-B, thereby preventing the binding of endogenous ligands and blocking receptor-mediated signaling by inhibiting angiogenesis, tumor growth, and the development of metastasis. Here, VEGFB is linked to neoplasm.